Krüppel样因子4在维持未分化甲状腺癌化疗耐药中的作用
本研究比较未分化甲状腺癌细胞与乳头状甲状腺癌细胞,发现未分化甲状腺癌细胞对紫杉醇耐药性更高且KLF4表达更高。敲低KLF4可上调甲状腺特异分化基因、降低多柔比星和紫杉醇耐药性并减少ABC转运体表达,小鼠成瘤实验显示紫杉醇联合KLF4敲低显著减小肿瘤质量。
要点
- 未分化甲状腺癌细胞HTH83、8505C、SW1736对紫杉醇耐药性及KLF4表达均高于TPC-1乳头状甲状腺癌细胞。
- 敲低KLF4可上调促甲状腺激素受体、甲状腺过氧化物酶、甲状腺球蛋白和钠碘同向转运体等分化基因。
- 紫杉醇联合KLF4敲低显著减小小鼠HTH83细胞来源肿瘤质量。
核心结论
- 未分化甲状腺癌细胞高表达KLF4,KLF4是维持其未分化表型和体内外耐药性所必需;本研究将KLF4确定为清除未分化甲状腺细胞的潜在治疗靶点。
研究设计与样本
- 体外比较未分化甲状腺癌细胞与乳头状甲状腺癌细胞在耐药性和基因表达上的差异,并检测KLF4敲低对体内外耐药性的影响。
- 检测KLF4过表达和敲低对ABC转运体活性的影响;荧光素酶报告实验检测ABCG2启动子活性。
- 小鼠成瘤实验检测紫杉醇联合KLF4敲低对HTH83细胞来源肿瘤质量的影响。
主要发现
- HTH83、8505C和SW1736等未分化甲状腺癌细胞对紫杉醇的耐药性及KLF4表达均高于TPC-1乳头状甲状腺癌细胞。
- 未分化甲状腺癌细胞敲低KLF4后,促甲状腺激素受体、甲状腺过氧化物酶、甲状腺球蛋白和钠碘同向转运体等分化基因表达增加。
- 未分化甲状腺癌细胞敲低KLF4后,对多柔比星和紫杉醇的耐药性降低、ABC转运体表达减少。
- 荧光素酶报告实验显示KLF4过表达增加ABCG2启动子活性,该作用被KLF4敲低消除。
- 成瘤实验显示紫杉醇联合KLF4敲低显著减小小鼠HTH83细胞来源肿瘤质量。
临床怎么用
- 原文结论认为KLF4是清除未分化甲状腺细胞的潜在治疗靶点,原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anaplastic thyroid cancer (ATC) has a very poor prognosis due to its aggressive nature and resistance to conventional treatment. Radiotherapy and chemotherapy are not fully effective because of the undifferentiated phenotype and enhanced drug resistance of ATC. The objective of this study was to evaluate the involvement of Krüppel-like factor 4 (KLF4), a stemness-associated transcription factor, in the undifferentiated phenotype and drug resistance of ATC. METHODS: ATC cells were compared to papillary thyroid cancer cells in drug resistance and gene expression. The effects of KLF4 knockdown in ATC cells on in vitro and in vivo drug resistance were measured. The effects of KLF4 overexpression and knockdown on ABC transporter activity were determined. RESULTS: ATC cells, such as HTH83, 8505C, and SW1736, exhibited higher resistance to the anticancer drug paclitaxel and higher expression of KLF4 than TPC-1 papillary thyroid cancer cells. Knockdown of KLF4 expression in ATC cells increased the expression of the thyroid-specific differentiation genes, such as thyrotropin receptor, thyroid peroxidase, thyroglobulin, and sodium-iodide symporter. Knockdown of KLF4 expression in ATC cells decreased the resistance to doxorubicin and paclitaxel, and reduced ABC transporter expression. Luciferase reporter assay results showed that KLF4 overexpression increased ABCG2 promoter activity, which was abolished by KLF4 knockdown. A tumorigenicity assay showed that the combination of paclitaxel treatment and KLF4 knockdown significantly decreased tumor mass originated from HTH83 cells in mice. CONCLUSIONS: ATC cells show high expression of KLF4, and KLF4 expression is necessary for maintaining the undifferentiated phenotype and drug resistance in vitro and in vivo. The present study identifies KLF4 as a potential therapeutic target for eliminating ATC cells.
引用
- Lee SI, Kim DK, Seo EJ, et al. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer. Thyroid. 2017. PMID: 28920531. doi:10.1089/thy.2016.0414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。